

0040-4020(95)00932-9

## Synthesis of *Pseudonucleosides* containing Chiral *Sulfahydantoins* as Aglycone (II) §

Georges DEWYNTER\*, Nourreddine AOUF<sup>◇</sup>, Zine REGAINIA<sup>◇</sup> and Jean-Louis MONTERO<sup>‡</sup>

Laboratoire de Chimie Biomoléculaire (Ura 1111 CNRS)  
 CC-073 Université de Montpellier II - Sciences et Techniques du Languedoc-  
 Pl. E. Bataillon 34 095 Montpellier cedex 05 France


**Key words:** chlorosulfonyl isocyanate, amino acids, carboxylsulfamide, Mitsunobu reaction, sulfahydantoin, thiadiazolidinone dioxide, glycosylation, pseudonucleoside.

**Abstract:** A series of chiral *sulfahydantoins* have been synthesized by alkaline cyclization starting from N-sulfamylaminoacid methyl esters. Regioselective glycosylation of these *pseudopyrimidic* heterocycles was carried out with a benzyl protecting group on the N-sulfonylcarbamic position. Best glycosylation results were obtained by preliminary silylation of sulfahydantoins, and their condensation with a tetraacylribofuranose which yielded the *pseudonucleosides* in a  $\beta$ -anomeric configuration.

### Introduction

The modification of the heterocyclic aglycone is important for the preparation of new nucleosidic analogues used in antiviral and/or antitumoral chemotherapy [1]. In order for a pseudonucleoside to interfere with biological processes, it must be able to inhibit nucleoside biogenesis enzymes, or to selectively hybridize with natural nucleotides. This induces subsequent reactions that interfere with duplication and transcription mechanisms in the neosynthesized biopolymer.

The proven mode of action of compounds such as showdomycine **2** [2] or pseudonucleosides containing hydantoins **3** [3] results from the structural analogy between non-natural aglycones and pyrimidines (i.e. thymidine, **1**).



- Fig 1-


§ part I: this journal (see ref. 4d).

\* e mail: dewynter@crit.univ-montp2.fr

◇ present address: Institut de Chimie, Université de Annaba, BP 12 El Hadjar, Algeria.

‡ correspondence and reprints

We describe here the preparation of a series of pseudo-nucleosides containing a sulfahydantoin (1,2,5-thiadiazolidin-3-one 1,1-dioxide) [4] as aglycone (Fig. 2). These *sulfa* analogues of nucleobases were derived from aminoacids by *insertion of a sulfamoyl group*, according to a previously reported approach [5]. Besides the interest that could have presented the introduction of this new heterocyclic base, the utilisation of natural aminoacids allows the variation of the size of the substituent R, the control of the chirality of the asymmetric carbon \*C<sub>4</sub>, and lastly the introduction of a functional group in the chain R (amine, carboxylic acid, thiol) able to react as bionucleophile.




-Fig 2-

## Chemistry

### Preparation of heterocyclic compounds

Sulfahydantoin **8** were synthesized in four steps (Scheme 1) starting from L-aminoesters **4** and chlorosulfonyl isocyanate (CSI) [5]. Initial sulfamoylation was followed by benzylation under Mitsunobu conditions [6], and then acidic treatment. Alkaline cyclization of N-sulfamoylaminoesters **7** thus obtained gave the desired heterocyclic compounds without racemization [4d], with an overall yield of 35-55% starting from the aminoester. It was also possible to directly obtain unprotected aglycones **10b-e** by cyclization, starting from Boc-sulfamides **5b-e** via intermediates **9b-e**.

The structure of the reaction products was confirmed by the usual methods: IR, <sup>1</sup>H and <sup>13</sup>C NMR and mass spectrometry. Boc-sulfamides **5b-e** were characterized by the presence in IR spectroscopy of two elongation bands of carbamate and ester carbonyles. Both NH were easily distinguished in NMR by the chemical shift and multiplicity for each of these two signals. The most acidic SO<sub>2</sub>-NH-COO proton appeared in the form of a singlet at 7-8 ppm. This signal disappears in alkylation compounds **6b-e**. Deprotection and cyclisation were equally followed in NMR by the disappearance of signals of the *tert*-butyl protons and methyl esters.




-fig 3-

Progressive increase in cyclization yields according to the steric bulk of R are observed. Surprisingly no cyclization was observed for compounds **13** and **14**, derived from β-alanine and proline respectively. In the first case, the unsubstituted chain showed a further rotational level, whereas in the second case the rigidity of the proline structure entails a dihedral angle S-N-C-C(O) that prevented the bicyclic fusion.


### Glycosylation

Three methods of glycosylation (Fig. 4) were used: the Vorbrüggen method (c), requiring preliminary silylation of the base [7], the Hilbert-Johnson's process [8] starting from the halogenosugars (b), and the direct fusion method (a) in the presence of a catalytic amount of iodine [9]. All these methods have been reviewed [10].



- a. X = OAc; Y = H . Δ; I<sub>2</sub>  
 b. X = Br; Y = H . DABCO  
 c. X = OAc; Y = Si(Me<sub>3</sub>)<sub>3</sub>. SnCl<sub>4</sub>


-Fig 4-



-Scheme 1-


Route b has been previously applied using commercial acetobromoglucose and benzothiadiazinone 11. Substitution was carried out in acetonitrile in the presence of diaza-[2.2.2]-bicyclooctane. The  $\beta$ -anomer of the N-glycoside 15 was obtained in 35% yield (fig 5).

Nucleophilic condensation starting from sulfahydantoin 8a-e and acetobromoglucose or triacetyl-1-chlororibose proved to be unsuccessful, due to thermal degradation of halosugars under the experimental conditions.



-Fig 5-

Condensation of peracylated D-ribose and aglycones 11, 8a and 8e (route a) yielded the expected pseudonucleosides  $\beta$  16, 17a and 17e. Starting from the unprotected sulfahydantoin 10e, the only product was that resulting from the reaction at N<sup>2</sup> condensation, the most acidic reactive site. This regioselectivity was established by NMR study of compound 18 (\*CH-NH signal appears as a doublet, that disappears after deuteration).




-Fig 6-


Route c proved to be a better method for glycosylation of sulfahydantoin. Compounds 8b-e were first treated under anhydrous argon atmosphere by hexamethyldisilazane (HMDS) containing catalytic quantities of ammonium sulphate. Condensation on the tribenzoyl-1-acetyl- $\beta$ -D-ribofuranose (a,b) or the tetraacetyl- $\beta$ -D-ribofuranose (c,d,e) was carried out in acetonitrile in the presence of tin tetrachloride. <sup>1</sup>H NMR did not unambiguously confirm the anomeric configuration of the obtained pseudonucleosides ( $J_{H1'H2} = 7.3-7.8$  Hz) but this method is known for its high stereoselectivity in the synthesis of  $\beta$ -anomers.

### Deprotection

Access to free pseudonucleosides 20 d-e -starting from their respective precursor 17- requires both N-debenzylation and deacylation. The first step was carried out by hydrogenolysis using Pd-C 5% and ammonium formate as hydrogen donor in refluxing ethanol. Under ultrasonic irradiation at room temperature, with the same catalyst and cyclohexadiene, the reaction time was shortened 4-fold. The ester groups were then removed by treatment with ammonia-methanol. Further debenzoylation of 18 gave the compound 21, regioisomer of 20e.



-Fig 7-



-Fig 8-

Computerized minimization [11] of structural parameters for the *pseudonucleoside* 20e (Fig.8, left) determined the preferential position for aglycone, the lower conformation energy ( $-7.9 \text{ kcal.mol}^{-1}$ ) and the value of dipolar moment  $\mu$ : 2.07u Debye. The dihedral angle H-C1'-C2'-H was  $155^\circ$  and the calculated  $J_{H1'H2'}$  was approximately 9Hz, according to the hypothesis of  $\beta$  configuration for the described series. For the hypothetical  $\alpha$ -epimer (Fig.8, right) an analogous determination of  $J_{H1'H2'}$  gave a value of 3.5 Hz.

### Conclusion

We describe here the preparation of new pseudonucleosides containing sulfamylated derivatives of natural amino acids as aglycones. According to our previous report, ring closure was performed without racemization (in contrast with hydantoins) and the heterocyclization was dependent on the steric bulk on C\*. Vorbrüggen's procedure proved to be well-suited for the  $N^5$ -glycosylation of benzyl-protected sulfahydantoins. The fusion method used for unprotected sulfahydantoins gave the  $N^2$  regioisomer. In both cases only one of the two anomers was obtained; this would appear to be the  $\beta$  configuration of this pseudoribonucleoside series, as suggested by previous reports and modeling calculations. The biological evaluation of the unprotected form of these congeners as antivirals, and their incorporation into synthetic RNA, are in progress.

### Acknowledgements

We would like to thank the French Ministry of Foreign Affairs for its financial support of international academic agreements 87 MES 73 and 93 MEN 234. Modeling calculations were performed with the helpful assistance of F.Cavelier-Fortin and J.Verducci (Ura 468 CNRS; Univ. of Montpellier II).

### Experimental section

Melting points were determined in open capillary tubes on a thermotechnical apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer spectrophotometer. Microanalysis were performed in the microanalysis laboratory of ENSCM (Montpellier). Ultraviolet spectra were recorded on a Cary 1186 spectrophotometer. Proton and Carbon Nuclear Magnetic Resonance were determined with a AC 250 Bruker spectrometer. Chemical shifts are expressed in parts per million, with TMS as reference. The multiplicity was indicated as: s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), l (large) and combination of these signals. Fast-atom bombardment mass spectra (FAB-MS) were recorded in positive or negative mode on a JEOL DX 300 spectrometer using the G, GT or NOBA matrix. Optical rotations were measured in a 1 cm cell on a Perkin-Elmer polarimeter. Thin Layer Chromatography (TLC) was performed on a precoated aluminium sheets of silicagel 60F254 (Merck). Column chromatography was performed with silicagel 60. All solvents used for the reactions were anhydrous.

### Methyl esters of [N-(N'-tert-butyloxycarbonyl)-sulfamoyl] amino acids

The synthesis of these compounds, starting from chlorosulfonyl isocyanate (CSI), *tert*-butanol and natural aminoacids was carried out according a general procedure previously described [4d].

#### Methyl [N-(N'-tert-butyloxycarbonyl)-sulfamoyl]-glycinate 5a

Yield=87%; Rf= 0,61 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); mp= 105-107°C IR (KBr, ν cm<sup>-1</sup>): 1748, 1716 (C=O, methyl and carb. esters); 1170, 1359 (SO<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm) 7.82 (s, 1H, NH-Boc); 5.90 (t, J=6.20 Hz, 1H, NH); 4.00 (d, J=6.20 Hz, 2H, CH<sub>2</sub>); 1.45 (s, 9H, tBu). MS (FAB<0, NOBA): 267 ([M-H]<sup>-</sup>). Anal. (C<sub>8</sub>H<sub>16</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 35.82; H 5.97; N 10.44; S 11.94 found % C 35.76; H 6.02; N 10.37; S 11.89.

#### [S(-)] Methyl [N-(N'-tert-butyloxycarbonyl)-sulfamoyl]-alaninate 5b

Yield=90%; Rf= 0.59 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub> = -14 (c=1 MeOH); mp= 72-74°C. IR (KBr, ν cm<sup>-1</sup>):1762, 1708 (C=O, methyl and carb. esters); 1152, 1365 (SO<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm) 7.72-7.00 (sl, 1H, NH-Boc); 5.82 (d, J=6.78 Hz, 1H, NH); 4.40 (qd, J<sub>1</sub>= 6.78, J<sub>2</sub> = 3.20 Hz, 1H, CH\*); 3.80 (s, 3H, OCH<sub>3</sub>); 1.55 (s, 9H, tBu); 1.45 (d, 6.76 Hz, 3H, CH<sub>3</sub>). MS (FAB<0, NOBA): 281 ([M-H]<sup>-</sup>); 181 ([M-Boc]<sup>-</sup>, 40%). Anal. (C<sub>9</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 38.29; H 6.38; N 9.92; S 11.34 found % C 38.22; H 6.41; N 9.88; S 11.37.

#### [S(+)] Methyl [N-(N'-tert-butyloxycarbonyl)-sulfamoyl]-valinate 5c

Yield=84%; Rf= 0.72 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub> = + 2.5 (c=1, MeOH); mp= 89-90°C. IR (KBr, ν cm<sup>-1</sup>): 1752, 1697 (C=O, methyl and carb. esters); 1357, 1152 (SO<sub>2</sub>). NMR (CDCl<sub>3</sub>, δ ppm) <sup>1</sup>H : 7-7.5 (sl, 1H, NH-Boc); 5.22 (s, 1H, NH); 4.15 (dd, 1H, CH\*); 3.78 (s, 3H, OCH<sub>3</sub>); 2.20 (m, 1H, CH<sub>β</sub>); 1.45 (s, 9H, tBu); 0.9 and 1.05 (2d, J=7.16Hz, 6H, 2 CH<sub>3</sub>). <sup>13</sup>C: 24.0 (2CH<sub>3</sub>); 24.5 (CH β); 27.5 (CH<sub>3</sub>-t Bu); 52.1 (CH<sub>3</sub>O); 58.2 (C\*); 84.4 (C-tBu); 152.8 (CO carbamate); 173.1 (CO ester). MS (FAB<0, matrix NOBA): 309 ([M-H]<sup>-</sup>); 235 ([M-OtBu]<sup>+</sup>). Anal. (C<sub>11</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 42.58; H 7.09; N 9.03; S 10.32. found % C 42. 73; H 7.22; N 9.14; S 10.18.

#### [S(-)] Methyl [N-(N'-tert-butyloxycarbonyl)-sulfamoyl]-leucinate 5d

Yield=83%; Rf= 0.67 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub> = -14.5 (c=1 MeOH); mp= 67-68°C. IR (KBr, ν cm<sup>-1</sup>): 1753, 1702 (C=O, methyl and carb. esters); 1358, 1162 (SO<sub>2</sub>); 3267, 2964 (NH). NMR (CDCl<sub>3</sub>, δ ppm) <sup>1</sup>H: 7.25 (m, 1H, NH); 5.80 (s, 1H, NH-C\* exch); 4.25 (t, J=6.20 Hz, 1H, CH\*); 3.64 (s, 3H, OCH<sub>3</sub>); 1.85 (m, 1H, ipr); 1.55 (d, J=6.18 Hz, 2H, CH<sub>2</sub> β); 1.48 (s, 9H, tBu); 0.95 (2d, J=3.60Hz, 2CH<sub>3</sub>). <sup>13</sup>C : 23.2 and 23.5 ([CH<sub>3</sub>]<sub>2</sub>CH); 27.5 (CH<sub>3</sub>-tBu); 42.2 (CH<sub>2</sub> β) 52.2 (CH<sub>3</sub>O); 57.9 (C\*); 84.4 (C-tBu); 150.8 (CO carbamate); 172.2 (CO meth. ester). MS (FAB<0, matrix GT): 323 ([M-H]<sup>-</sup>); 249 ([M-OtBu]<sup>-</sup>); 223 ([M-Boc]<sup>-</sup>). Anal. (C<sub>12</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 44.44; H 7.50; N 8.64; S 9.87; found C 44.64; H 7.53; N 8.48; S 9.85.

#### [S(+)] Methyl [N-(N'-tert-butyloxycarbonyl)-sulfamoyl]-phenylalaninate 5e

Yield 87%; Rf= 0.68 (CHCl<sub>3</sub>-MeOH 9-1); [α]<sub>D</sub> = +12 (c=1; MeOH); mp=131-132°C. IR (KBr, ν cm<sup>-1</sup>): 1753, 1702 (C=O methyl and carb. esters); 1358, 1162 (SO<sub>2</sub>); 3267, 2964 (NH). NMR (CDCl<sub>3</sub>, δ ppm) <sup>1</sup>H: 7.30 (m, 3H, Ar-H); 7.20 (m, 2H, Ar-H ortho); 7.10 (s, 1H, NH exch); 5.60 (d, J=8.2 Hz, 1H, NHα exch); 4.50 (m, 1H, CH\*); 3.70 (s, 3H, OCH<sub>3</sub>); 3.10 (2dd, J= 2.7 and 6Hz, 2H, CH<sub>2</sub> Bn); 1.45 (s, 9H, tBu). <sup>13</sup>C : 27.2 (3 CH<sub>3</sub> tBu); 39.2 (CH<sub>2</sub> Bn); 51.8 (CH<sub>3</sub>O); 57.5 (C\*); 84.1 (C tBu); 127.3 (C-para); 128.8 (C-ortho); 130.0 (C meta); 135.7 (C-ipso); 152.7 (CO carbamate); 172.1 (CO ester). MS (NOBA, FAB<0): 357 ([M-H]<sup>-</sup>); 283 ([M-OtBu]<sup>-</sup>). Anal. (C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 50.27; H 6.14; N 7.82; S 8.93. found % C 50.21; H 6.13; N 7.78; S 8.90.

### General procedure of Mitsunobu reaction

A solution of [Boc-sulfamide] aminoester (0.01M) 5a-e and diethyl (isopropyl) azodicarboxylate (0.01M; 1.74g or 2.02 g) in THF (8mL) was added dropwise (15mn, 5°C) to a solution of equimolar quantities of triphenylphosphine (2.52g) and benzylic alcohol (1.08g; 1.06 mL) in THF (8mL). The reaction medium was stirred under atmosphere of dry nitrogen for about 45 min. TLC reveals the formation of substituted compound

(UV, ninhydrine) less polar than its precursor. Oxydoreduction compounds were removed by filtration after precipitation into diethylether. The filtrate was concentrated and the crude residue was purified by column chromatography eluted with dichloromethane. Benzylated sulfamides **6a-e** were recovered in 80-95 % yield.

*Methyl [N-(N'-tert-butyloxycarbonyl, N'-benzyl)-sulfamoyl]-glycinate 6a*

**Yield** 82%; **Rf**= 0.63 (CHCl<sub>3</sub>-MeOH 9-1); **mp**= 60-62°C. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1746, 1704 (C=O methyl and carb. esters); 1362, 1169 (SO<sub>2</sub>); **<sup>1</sup>H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) : 7.35 (m, 5H, Ar-H); 6.15 (t, J=5.89 Hz, 1H, NH exch); 4.65 (s, 2H, CH<sub>2</sub> Bn); 4.03 (d, J=5.89 Hz, 2H, CH<sub>2</sub>); 3.70 (s, 3H, OCH<sub>3</sub>); 1.48 (s, 9H, tBu). **MS** (FAB>0, NOBA): 359 ([M+H]<sup>+</sup>); 259 ([M-Boc]<sup>+</sup>). **Anal.** (C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 50.27; H 6.14; N 7.82; S 8.93 found % C 50.52; H 6.02; N 7.62; S 8.88.

*[(S)(-)] Methyl [N-(N'-tert-butyloxycarbonyl, N'-benzyl)-sulfamoyl]-alaninate 6b*

**Yield** 88%; **Rf**= 0.68 (CHCl<sub>3</sub>-MeOH 9-1);  $[\alpha]_D^{25}$  = -12 (c=1; MeOH); **mp**=54-55°C. **IR** (KBr,  $\nu$  cm<sup>-1</sup>) 1754, 706 (C=O methyl and carb. esters); 1374, 1165 (SO<sub>2</sub>); **<sup>1</sup>H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) 7.35 (m, 5H, Ar-H); 5.90 (d, J=7.20 Hz, 1H, NH); 4.70-4.90 (2d, J=15.57Hz, 2H, CH<sub>2</sub> Bn); 3.75 (s, 3H, OCH<sub>3</sub>); 1.50 (s, 9H, tBu); 1.30 (d, J=7.15 Hz, 3H, CH<sub>3</sub>). **MS** (FAB>0, NOBA) 373 ([M+H]<sup>+</sup>); 317 ([M-tBu]<sup>+</sup>); 273 ([M-Boc]<sup>+</sup>). **Anal.** (C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 51.61; H 6.45; N 7.52; S 8.60 found % C 51.52; H 6.41; N 7.49; S 8.64.

*[(S)(-)] Methyl [N-(N'-tert-butyloxycarbonyl, N'-benzyl)-sulfamoyl]-valinate 6c.*

**Yield** 83%; **Rf**= 0.76 (CHCl<sub>3</sub>-MeOH 9-1);  $[\alpha]_D^{25}$  = -9 (c=1; MeOH); **mp**=50°C. **IR** (KBr,  $\nu$  cm<sup>-1</sup>) 3300, 3240 (NH) 1750, 1720 (C=O methyl and carb. esters); 1370, 1167 (SO<sub>2</sub>); **<sup>1</sup>H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) 7.25 (m, 5H, Ar-H); 5.75 (d, J=8.80 Hz, 1H, NH); 4.70 (2d, Jgem= 15.5Hz, 2H, CH<sub>2</sub> Bn); 3.60 (s, 3H, OCH<sub>3</sub>); 3.55 (m, 1H, CH\*); 1.95 (m, 1H, CH $\alpha$ ); 1.48 (s, 9H, tBu); 0.75- 0.85 (2d, J=6.45 Hz, 6H, 2CH<sub>3</sub>). **MS** (FAB>0, NOBA): 401 ([M+H]<sup>+</sup>); 301 ([M-Boc]<sup>+</sup>). **Anal.** (C<sub>18</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 54.00; H 7.00; N 7.00; S 8.00 found % C 54.14; H 7.07; N 6.92; S 7.92.

*[(S)(-)] Methyl [N-(N'-tert-butyloxycarbonyl, N'-benzyl)-sulfamoyl]-leucinate 6d.*

**Yield** 84%; **Rf**= 0.73 (CHCl<sub>3</sub>-MeOH 9-1);  $[\alpha]_D^{25}$  = -18 (c=1; MeOH); **mp**=50°C. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 3290, 3220 (NH) 1754, 1722 (C=O methyl and carb. esters); 1368, 1160 (SO<sub>2</sub>); **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H**: 7.35 (m, 5H, Ar-H); 5.75 (d, J=8.80 Hz, 1H, NH); 4.70-4.90 (Jgem=15.36Hz, CH<sub>2</sub>-N); 3.85 (q, J=8.78 Hz, 1H, CH\*); 3.60 (s, 3H, OCH<sub>3</sub>); 1.75 (m, 1H, iPr); 1.52 (s, 9H, tBu); 0.95-0.85 (2d, J=3.86 Hz, 6H, 2CH<sub>3</sub>). **<sup>13</sup>C** 21.8, 22.9 (iPr); 27.5 (3 CH<sub>3</sub> tBu); 41.2 (C $\beta$ ); 50.4 (CH<sub>2</sub> Bn); 51.9 (CH<sub>3</sub>O); 54.7 (C\*); 84.2 (C-tBu); 126.5, 126.9, 128.0 (C-Ar); 135.8 (C Ar-ipso); 152.2 (CO carbamate); 172.6 (CO ester). **MS** (FAB>0, NOBA): 415 ([M+H]<sup>+</sup>); 359 ([M-tBu]<sup>+</sup>); 315 ([M-Boc]<sup>+</sup>). **Anal.** (C<sub>19</sub>H<sub>30</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 55.07; H 7.24; N 6.76; S 7.72 found % C 55.21; H 7.19; N 6.73; S 7.76.

*[(S)(+)] Methyl [N-(N'-tert-butyloxycarbonyl, N'-benzyl)-sulfamoyl]-phenylalaninate 6e*

**Yield** 95%; **Rf**= 0.68 (CHCl<sub>3</sub>-MeOH 9-1);  $[\alpha]_D^{25}$  = +3 (c=1; MeOH); **mp**=85-87°C. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 3301, 3241 (NH) 1746, 1714 (C=O methyl and carb. esters); 1377, 1166 (SO<sub>2</sub>); **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H**: 7.35 (m, 10H, 2Ar-H); 5.75 (d, J=7.35 Hz, 1H, NH-exch); 4.72-4.90 (2d, Jgem=15.60Hz, CH<sub>2</sub> Bn); 4.00 (q, J=7.30 Hz, 1H, CH\*); 3.60 (s, 3H, OCH<sub>3</sub>); 3.00 (2dd, Jvic= 5.77 Hz, Jgem=19Hz, 2H, CH<sub>2</sub>-C\*); 1.48 (s, 9H, tBu). **<sup>13</sup>C**: 27.4 (3 CH<sub>3</sub>-tBu); 38.7 (CH<sub>2</sub>-Bn); 50.2 (CH<sub>2</sub> -N) 52.3 (CH<sub>3</sub>O); 57 (C\*); 84.4 (C-t Bu); 126.8 ; 129.2 ; 129.2 ; 135.7 (C-Ar); 150.1 (CO carbamate); 172.3 (CO ester). **MS** (FAB>0, matrice NOBA): 449 ([M+H]<sup>+</sup>); 393 ([M-Isobutene]<sup>+</sup>); 393 ([M-Boc]<sup>+</sup>). **Anal.** (C<sub>22</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S) calc % C 58.93; H 6.25; N 6.25; S 7.14 found % C 58.69; H 6.19; H 6.29; S 7.10.

**General procedure for acidic decarbamylation**

A solution of trifluoroacetic acid (3 Eq) in dichloromethane (v/v) was added dropwise to the N-Boc (benzyl) sulfamides **6 (5) a-e** (5.10<sup>-3</sup> M) dissolved in the same solvent (50 mL). The reaction medium was stirred for 2 hours, concentrated under reduced pressure and coevaporated with diethyl ether. Residue was recrystallized from dichloromethane; the deprotected sulfamides **7-9** were obtained in 85-95% yield.

*Methyl [N-(N'-benzyl)-sulfamoyl]-glycinate 7a*

**Yield**= 89%; **Rf**=0.62 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); foam. **<sup>1</sup>H NMR** (DMSO D<sub>6</sub>,  $\delta$  ppm) 7.42 (m, 5H, Ar-H); 5.75 (t, J=5.44 Hz, 1H, NH); 5.25 (sl, 1H, NH-Bn); 4.05 (d, 2H, CH<sub>2</sub> Bn); 3.70 (d, J=5.44 Hz, 2H, CH<sub>2</sub>-N); 3.65 (s, 3H, OCH<sub>3</sub>). **MS** (FAB>0, matrix NOBA): 259 ([M+H]<sup>+</sup>); 517 ([2M+H]<sup>+</sup>). **Anal.** (C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 46.51; H 5.42; N 10.85; S 12.40 found % C 46.44 ; H 5.60; N 10.78 ; S 12.68.

*Methyl [N-(N'-benzyl)-sulfamoyl]-alaninate 7b*

**Yield**= 92%; **Rf**=0.68 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-5); foam, **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H** 7.35 (s, 5H, Ar-H); 5.10 (d, J=9.98 Hz, 1H, NH $\alpha$ ); 4.60 (s broad, 1H, NH-Bn); 4.15 (2d, Jgem=15.64 Hz, 2H, CH<sub>2</sub> Bn); 4.05 (q, J=7.06 Hz,

1H, CH\*); 3.60 (s, 3H, OCH<sub>3</sub>); 1.45 (d, J=7.06 Hz, 3H, CH<sub>3</sub> Ala). MS (FAB>0, matrix NOBA): 273 ([M+H]<sup>+</sup>). Anal. (C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 48.52; H 5.88; N 10.29; S 11.76 found % C 48.44; H 5.91; N 10.23; S 11.71.

*Methyl [N-(N'-benzyl)-sulfamoyl]-valinate 7c*

Yield= 95%; Rf=0.65 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95-5); foam; [α]<sub>D</sub>= -11 (c=1 MeOH). 1H NMR (CDCl<sub>3</sub>, δ ppm) 7.35 (m, 5H, Ar-H); 5.40 (s broad, 2H, 2NH); 4.15 (s, 2H, CH<sub>2</sub> Bn); 3.80 (d, J= 4.70 Hz, 1H, CH\*); 3.65 (s, 3H, OCH<sub>3</sub>); 2.10 (m, 1H, iPr); 0.85-0.95 (2d, J=6.80 Hz, 6H, 2CH<sub>3</sub>). MS (FAB>0, matrix NOBA): 301([M+H]<sup>+</sup>). Anal. (C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 52.00; H 6.66; N 9.33; S 10.66 found % C 51.89; H 6.69; N 9.28; S 10.63.

*Methyl [N-(N'-benzyl)-sulfamoyl]-leucinate 7d*

Yield= 93%; Rf=0.64 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); foam, [α]<sub>D</sub>= -12 (c=1 MeOH); NMR (CDCl<sub>3</sub>, δ ppm) 1H 7.35 (m, 5H, Ar-H); 4.85 (d, J= 9.78 Hz, 1H, NHα); 4.45 (t, J= 6.03 Hz, 1H, NH-Bn); 4.15 (d, J=5.58 Hz, 2H, CH<sub>2</sub> Bn); 4.05 (m, 1H, CH\*); 3.06 (s, 3H, OCH<sub>3</sub>); 1.70-1.85 (m, 1H, isobut); 1.40-1.50 (m, 2H, CH<sub>2</sub> leu); 0.90-1.00 (2d, J=3.98 Hz, 6H, 2CH<sub>3</sub>). <sup>13</sup>C 21.7, 23.5 (iPr); 40.5 (Cb); 48.6 (CH<sub>2</sub>-Bn); 52.6 (CH<sub>3</sub>O); 55.1 (C\*); 126.3, 126.8, 128.3 (C Ar, o, m, p); 137.0 (C ipso); 173.8 (CO ester). MS (FAB>0, matrix NOBA): 315 ([M+H]<sup>+</sup>); 629 ([2M+H]<sup>+</sup>). Anal. (C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 53.50; H 7.00; N 8.91; S 10.19 found % C 53.57; H 7.06; N 8.80; S 10.13.

*Methyl [N-(N'-benzyl)-sulfamoyl]-phenylalaninate 7e*

Yield= 92%; Rf= 0.71 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); mp= 126-128°C. 1H NMR (CDCl<sub>3</sub>, δ ppm) : 7.35-7.15 (m, 10H, 2Ar-H); 4.90 (d, J=9.4Hz, 1H, NH exch), 4.45 (t, J=16.3 Hz, 1H, NH-Bn exch), 4.40 (m, 1H, CH\*); 4.05 (2dd, Jvic=5.43 Hz, Jgem=16.25 Hz, 2H, CH<sub>2</sub> Bn); 3.70 (s, 3H, OCH<sub>3</sub>); 3.25 (2dd, Jvic=5.86 Hz, Jgem=16.32 Hz, CH<sub>2</sub> β). MS (FAB>0, matrix NOBA) 349 ([M+H]<sup>+</sup>); 697 ([2M+H]<sup>+</sup>). Anal. (C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 58.62; H 5.74; N 8.04; S 9.19 found % C 58.72; H 5.69; N 8.01; S 9.16.

**Synthesis of sulfahydantoins and their N<sup>2</sup>-benzyl derivatives; general procedure.**

Headline cyclized compounds were obtained by addition of NaOH 4N (5mL) to N-sulfamoylaminoesters 9a-e or their N-benzyl homologues 7a-e (10-2 mole) in 50 mL of ethanol. After 1h stirring, HCl 10 N were added dropwise (up to pH1) then distilled water (50ml). The medium was extracted with dichloromethane, concentrated under vacuum and purified by chromatography. The first fraction afforded the expected products. The aqueous phase of the extraction contains the saponified sulfamoylamino acid in 10-30% yield.

*N-2-benzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 8a*

Yield= 62%; Rf= 0.64 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); mp= 52°C. IR (KBr, v cm<sup>-1</sup>): 1724 (C=O). 1H NMR (CDCl<sub>3</sub>, δ ppm): 7.35 (m, 5H, Ar-H); 4.75 (t, J=7.80 Hz, 1H, NH); 4.65 (s, 2H, CH<sub>2</sub> Bn); 4.05 (d, J=7.80 Hz, 2H, CH<sub>2</sub>). MS (FAB>0, matrix GT) 227 ([M+H]<sup>+</sup>). Anal. (C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 47.78; H 4.42; N 11.38; S 14.16 found % C 47.64; H 4.38; N 11.42; S 14.09.

*(S)(-)] N-2-benzyl-4-methyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 8b*

Yield= 64%; Rf= 0.66 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub>= -29. (c=1, CHCl<sub>3</sub>); mp= 98-99°C. IR (KBr, v cm<sup>-1</sup>): 1721 (C=O). 1H NMR (CDCl<sub>3</sub>, δ ppm): 7.40 (m, 5H, Ar-H); 4.80 (s, 1H, NH exch); 4.75 (s, 2H, CH<sub>2</sub> Bn); 4.35 (m, 1H, CH\*); 1.60 (d, J=6.88 Hz, 3H, CH<sub>3</sub>). MS (FAB>0, matrix GT) 241 ([M+H]<sup>+</sup>). Anal. (C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 50.00; H 5.00; N 11.67; S 13.33 found % C 50.46; H 5.06; N 11.54; S 13.26.

*[(S)(-)]N-2-benzyl-4-isopropyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 8c*

Yield= 71%; Rf= 0.65 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub>= -112 (c=1, CHCl<sub>3</sub>); mp= 63-65°C. IR (KBr, v cm<sup>-1</sup>): 1715 (C=O). 1H NMR (CDCl<sub>3</sub>, δ ppm): 7.55-7.35 (m, 6H, 5Ar-H, NH); 4.70 (s, 2H, CH<sub>2</sub> Bn); 4.15 (m, 1H, CH\*); 2.30 (m, 1H, CH-iPr); 0.90-1.10 (2d, J=6.96 Hz, 6H, 2CH<sub>3</sub>). MS (FAB>0, matrix GT) 269 ([M+H]<sup>+</sup>). Anal. (C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 53.73; H 5.97 ; N 10.44; S 11.94 found % C 53.62; H 5.96; N 10.38; S 11.89.

*[(S)(-)] N-2-benzyl-4-isobutyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 8d*

Yield= 77%; Rf= 0.66 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [α]<sub>D</sub>= -75 (c=1, CHCl<sub>3</sub>); mp= 62-64°C. IR (KBr, v cm<sup>-1</sup>): 1724 (C=O). NMR (CDCl<sub>3</sub>, δ ppm) 1H 7.35 (m, 5H, Ar-H); 4.64 (s, 2H, CH<sub>2</sub> Bn); 4.05 (m, 1H, CH\*); 1.75 (m, 2H, CH<sub>2</sub> β); 1.60 (m, 1H, CH); 0.70-0.80 (2d, J=6.50 Hz, 6H, 2CH<sub>3</sub>). <sup>13</sup>C 21.8 (2CH<sub>3</sub> iPr); 24.8 (CH iPr); 40.3 (CH<sub>2</sub> β); 44.7 (CH<sub>2</sub> Bn); 60.2 (C\*); 126.6, 127.3, 127.9 (C Ar o, p, m); 135.2 (C Bn ipso); 171.6 (CO ester). MS (FAB>0, matrix GT) 283 ([M+H]<sup>+</sup>). Anal. (C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 55.31; H 6.38 ; N 9.92; S 11.34 found % C 55.17; H 6.43; N 9.85; S 11.39.



**[(S)(+)] N-2,4-dibenzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 8e**

**Yield= 82%; Rf= 0.70** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = +73 (c=1, CHCl<sub>3</sub>); **mp= 67-69°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1722 (C=O). **<sup>1</sup>H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) 7.10-7.35 (m, 10H, Ar-H); 4.70 (2d, Jgem=14 Hz, 2H, CH<sub>2</sub> Bn); 4.60 (d, J=7.90 Hz, 1H, NH, exch); 4.30 (m, 1H, C\*H); 3.05 (2dd, Jgem=15 Hz, Jvic1= 7.85, Jvic2=4.55 Hz, 2H, CH<sub>2</sub>  $\beta$ ). **MS** (FAB>0, matrix GT) 317 ([M+H]<sup>+</sup>). **Anal.** (C<sub>16</sub>H<sub>16</sub>O<sub>3</sub>N<sub>2</sub>S) calc % C 60.75; H 5.06 ; N 8.86; S 10.12 found % C 60.61; H 5.09; N 8.78; S 10.07.

**[(S)(-)] Methyl [N-sulfamoyl]-alaninate 9b**

**Yield=96%; Rf= 0.46** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = -18 (c=1 MeOH); **mp= 67-68°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1746 (C=O); 1341, 1149 (SO<sub>2</sub>); 3330, 3270, 3250 (NH). **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H** : 7.05 (d, J=8.8Hz, NH); 6.62 (s, 2H, NH<sub>2</sub>); 4.20 (dt, 1H, J=8.8Hz et 7.2Hz, CH\*); 3.65 (s, 3H, OCH<sub>3</sub>); 1.45 (d, J=7.2 Hz, 3H, CH<sub>3</sub>). **<sup>13</sup>C** 17 (CH<sub>3</sub>); 50.9 (C\*); 51.8 (OCH<sub>3</sub>); 173 (CO) **MS** (FAB>0, NOBA): 183 ([M+H]<sup>+</sup>). **Anal.** (C<sub>4</sub>H<sub>10</sub>N<sub>2</sub>O<sub>4</sub>S) calc C 26.37; H 5.49; N 15.38; S 17.58 found C 26.45; H 5.42; N 15.28; S 17.86.

**[(S)(+)] Methyl [N-sulfamoyl]-valinate 9c**

**Yield= 97%; Rf=0.46** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = +9.5 (c=1 MeOH); **mp= 58-60°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1748 (C=O) ; 1352, 1158 (SO<sub>2</sub>); 3310 and 2960 (NH). **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H**: 6.40 (d, J=8.25 Hz, 1H, NH); 5.45 (s, 2H, NH<sub>2</sub>); 4.15 (dd, J=7.13 Hz, 1H, CH\*); 3.78 (s, 3H, OCH<sub>3</sub>); 2.20 (s, 1H, CH $\beta$ ); 0.9 et 1.05 (2d, J=7.16Hz, 6H, 2 CH<sub>3</sub>). **<sup>13</sup>C**: 23.7 (2 CH<sub>3</sub>); 24.3 (CH  $\beta$ ); 51.7 (CH<sub>3</sub>O); 58.2 (C\*); 172.6 (CO methyl ester) **MS** (FAB<0, matrice NOBA): 209 ([M-H]<sup>-</sup>). **Anal.** (C<sub>6</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 34.28; H 6.66; N 13.33; S 15.23 found % C 34.42; H 6.72; N 13.02; S 15.03.

**[(S)(-)] Methyl [N-sulfamoyl]-leucinate 9d**

**Yield=96%; Rf=0.47** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = -21.5 (c=1 MeOH); **mp= 62-64°C** **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1751 (C=O) ; 1348, 1154 (SO<sub>2</sub>); 3310 and 2960 (NH). **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H** : 5.80 (s, 1H, NH exch); 5.20 (s, 2H, NH<sub>2</sub>); 4.25 (t, J=7.40 Hz, 1H, CH\*); 3.66 (s, 3H, OCH<sub>3</sub>); 1.85 (m, 1H, iPr); 1.55 (m, 2H, CH<sub>2</sub>  $\beta$ ); 0.93 (2d, J=6.80 Hz, 6H, 2CH<sub>3</sub>). **<sup>13</sup>C**: 22.5 (2CH<sub>3</sub> iPr); 23.5 (CH $\gamma$ ); 41.9 (CH  $\beta$ ); 52.0 (CH<sub>3</sub>O); 57.4 (C\*); 172.8 (CO). **MS** (FAB>0, NOBA): 225 ([M+H]<sup>+</sup>, 45%). **Anal.** (C<sub>7</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 37.50; H 7.14; N 12.50; S 14.28 found % C 37.36; H 7.19; N 12.42; S 14.25.

**[(S)(+)] Methyl [N-sulfamoyl]-phenylalaninate 9e**

**Yield=97%; Rf=0.52** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = +45 (c=1 MeOH); **mp= 64°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 3480 (NH); 1745 (CO). **NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) **<sup>1</sup>H** : 7.25 (m, 5H, Ar-H); 5.50 (d, 1H, J=8.5Hz, NH); 5.00 (s, 2H, NH<sub>2</sub>); 4.30 (dt, 1H, CH $\alpha$ ); 3.65 (s, 3H, OCH<sub>3</sub>); 3.00 (2dd, J<sub>1</sub>=5.54Hz, J<sub>2</sub>=6.71Hz, Jgem=19.31Hz, 2H, CH<sub>2</sub>). **<sup>13</sup>C**: 39.7 (CH<sub>2</sub>Bn); 52.5 (CH<sub>3</sub>O); 58.6 (C\*); 127.7 (C-para); 129.8 (C-ortho); 129.9 (C-meta); 137.3 (C-ipso); 173.5 (CO ester). **MS** (FAB>0, NOBA): 259 ([M+H]<sup>+</sup>). **Anal.** (C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S) calc % C 46.51; H 5.42; N 10.85 S 12.40 found % C 46.42; H 5.37; N 10.78; S 12.30.

**[(S)(-)] 4-methyl-1,2,5-thiadiazolidin-3-one dioxide 10b**

**Yield= 56%; Rf= 0.38** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = -12 (c=1, CHCl<sub>3</sub>); **mp= 86-87°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1720 (C=O). **NMR** **<sup>1</sup>H** (CDCl<sub>3</sub>,  $\delta$  ppm): 8.50 (s, 1H, NH, exch); 4.32 (m, 1H, CH\*); 1.50 (d, J=7.2 Hz, 3H, CH<sub>3</sub>). **<sup>13</sup>C**: 17 (CH<sub>3</sub>); 59 (C\*), 174 (CO). **MS** (FAB>0, matrix GT) 149 ([M+H]<sup>+</sup>). **Anal.** (C<sub>3</sub>H<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 24.00; H 4.00; N 18.66; S 21.33 found % C 24.06; H 4.03; N 18.43; S 21.17.

**[(S)(-)] 4-isopropyl-1,2,5-thiadiazolidin-3-one dioxide 10c**

**Yield= 61%; Rf= 0.32** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = -18 (c=1, CHCl<sub>3</sub>); **mp= 108-110°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1721 (C=O). **<sup>1</sup>H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm): 8.48 (s, 1H, NH); 5.25 (d, J=7.80 Hz, 1H, NH-C\*); 4.15 (m, 1H, CH\*); 2.35 (m, 1H, CH iPr); 0.9-1.1 (2d, J=6.90 Hz, 6H, 2CH<sub>3</sub>). **MS** (FAB>0, matrix GT) 179 ([M+H]<sup>+</sup>). **Anal.** (C<sub>5</sub>H<sub>10</sub>O<sub>3</sub>N<sub>2</sub>S) calc % C 33.70; H 5.61; N 15.73; S 17.97 found % C 33.54; H 5.55; N 15.59; S 17.83.

**[(S)(-)] 4-isobutyl-1,2,5-thiadiazolidin-3-one dioxide 10d**

**Yield= 80%; Rf= 0.45** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = -25 (c=1, CHCl<sub>3</sub>); **mp= 122°C**. **IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1718 (C=O). **<sup>1</sup>H NMR** (DMSO D<sub>6</sub>,  $\delta$  ppm): 8.50 (s, 1H, NH-CO); 5.35 (d, J=7.20 Hz, 1H, NH); 4.50 (m, 1H, CH\*); 0.85-0.95 (2d, J=6.42 Hz, 6H, 2CH<sub>3</sub>); 1.75 (m, 1H, iPr); 1.55 (m, 2H, CH<sub>2</sub> $\beta$ ). **MS** (FAB>0, matrix GT) 191 ([M+H]<sup>+</sup>). **Anal.** (C<sub>6</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 37.50; H 6.25; N 14.58; S 16.66 found % C 37.43; H 6.22; N 14.63; S 16.69.

**[(S)/(+)] 4-benzylthia-2,5-diazolidin-3-one 1,1-dioxide 10e**

**Yield= 78%; Rf= 0.42** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); [ $\alpha$ ]<sub>D</sub> = +89 (c=1, CHCl<sub>3</sub>); **mp= 197-198°C. IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1719 (C=O). **NMR** (DMSO D<sub>6</sub>,  $\delta$  ppm) **1H**: 8.20 (sl, 1H, NH, exch); 7.32 (m, 6H, 5 Ar-H and NH $\beta$ ); 4.42 (m, 1H, C\*H); 3.10 and 2.80 (2dd, Jg=14 Hz; Jv=4 Hz; CH<sub>2</sub>  $\beta$ ). **13C** (CDCl<sub>3</sub>,  $\delta$  ppm): 37.2 (CH<sub>2</sub>); 61.9 (C\*); 127.7, 128.3, 128.7, 136.2 (C-Ar); 171.5 (CO). **MS** (FAB>0, matrix GT) 225 ([M+H]<sup>+</sup>). **Anal.** (C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 47.78; H 4.42; N 12.4; S 14.15 found % C 47.54; H 4.38; N 12.56; S 14.08.

**N<sup>2</sup>-Benzyl-benzothiadiazolidinone 11**

**Yield= 80%; Rf= 0.42** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); **mp= 184-186°C. IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1705 (C=O). **1H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm): 8.10 (d, J=6.40 Hz, 1H, Hd); 7.70 (t, J=6.32 Hz, 1H, Hc); 7.35 (m, 6H, Ar (Bn)+Hd); 7.15 (d, 1H, J=7.6 Hz, Ha), 5.05 (s, 2H, CH<sub>2</sub> Bn). **MS** (FAB>0, matrix GT) 289 ([M+H]<sup>+</sup>). **Anal.** (C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 58.33; H 4.16; N 9.72; S 11.11 found % C 58.17; H 4.23; N 9.65; S 11.05.

**Benzothiadiazinone 12**

**Yield= 71%; Rf= 0.34** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); **mp= 229-230°C. IR** (KBr,  $\nu$  cm<sup>-1</sup>): 1679 (C=O). **1H NMR** (DMSO D<sub>6</sub>,  $\delta$  ppm): 10.70 (s, 1H, NH-CO); 7.90 (d, J=6.40 Hz, 1H, Hd); 7.65 (d, J=6.60 Hz, 1H, Ha); 7.50 (t, J=7.60 Hz, 1H, Hb); 7.20 (t, J=6.60 Hz, 1H, Hc); 6.65 (s, 1H, NH). **MS** (FAB>0, matrix GT) 197 ([M+H]<sup>+</sup>). **Anal.** (C<sub>7</sub>H<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S) calc % C 42.42; H 3.03; N 14.14; S 16.16 found % C 42.54; H 3.09; N 14.02; S 16.11.

**General procedure for nucleosidic condensation**

**way a** An equimolar mixture of solid sulfahydantoin (or its N-benzyl homologue) and 1,2,3,5-tetra-O-acyl-( $\beta$ ,D)-ribofuranose was heated (155°C) with 0.4 % iodine *in vacuo* (20 mm Hg) for 30 mn. The resulting residue was purified by column chromatography (eluent: dichloromethane:MeOH 9:1) to give the nucleoside.

**way b** A solution of equimolar quantities of sulfahydantoin (1mmole) and acetobromoglucose in acetonitrile was refluxing with DABCO (2Eq) during 4 hours. The solvent was removed *in vacuo* and the residue was dissolved in dichloromethane. The organic layer was washed with water and dried with anhydrous sodium sulphate. Purification step was identical to the above described procedure.

**way c** Sulfahydantoin (5.10<sup>-3</sup> M) in hexamethyldisilazane (HMDS) as solvent was refluxing 24h under argon atmosphere. Then the silylating agent was removed *in vacuo* and a solution of acylated sugar (1 Eq) and tin tetrachloride (2 Eq) in 10 mL acetonitrile were successively added. The reaction medium was heating to 60°C during 24h and finally concentrated, washed with a hydrogencarbonate solution, dried and purified in the same conditions as previous procedures.

**N<sup>2</sup>-benzyl-N<sup>6</sup>-[2,3,4,6-tetra-O-acetyl-( $\beta$ -D)-glucopyranos-1-yl]-benzo-1,2,6-thiadiazin-3-one 1,1-dioxide 15**

(way b) **Yield= 23%; Rf= 0.72** (CH<sub>2</sub>Cl<sub>2</sub> -MeOH 9-1); **mp= 64-65°C; 1H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm): 8.15 (d, J=6.32 Hz, 1H, Hd); 7.70 (t, J=7.70 Hz, 1H, Hb); 7.5-7.1 (m, 7H, Ar-H); 5.40 (d, 1H, J=10.8 Hz, H<sub>1'</sub>); 5.9 (m, 1H, H<sub>4'</sub>); 5.15 (dd, J=10.80 Hz, 1H, H<sub>2'</sub>); 5.00 (dd, 1H, H<sub>3'</sub>); 4.95 (2d, J=15 Hz, 2H, CH<sub>2</sub> Bn); 3.80-4 (2dd, 2H, H<sub>6'</sub> et H<sub>6''</sub>); 3.55 (td, 1H, H<sub>5'</sub>); 2.00-2.10 (3s, 9H, 3CH<sub>3</sub> Ac). **MS** (FAB>0, matrix NOBA): 619 ([M+H]<sup>+</sup>). **Anal.** (C<sub>28</sub>H<sub>30</sub>N<sub>2</sub>O<sub>12</sub>S) calc % C 54.36; H 4.85; N 4.53; S=5.17 found % C 54.28; H 4.81; N 4.59; S 5.21.

**N<sup>2</sup>-benzyl-N<sup>6</sup>-[2,3,5-tri-O-acetyl-( $\beta$ -D)-ribofuranos-1-yl]-benzo-1,2,6-thiadiazin-3-one 1,1-dioxide 16**

(way a) **Rf= 0.76** ( MeOH- CH<sub>2</sub>Cl<sub>2</sub> 95-5). **1H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm) : 8.10 (dd, J=1.58 and 7.75 Hz, 1H, Ar-Hd), 7.65-7.60 (td, J=1.62 and 7.72 Hz, 1H, Hb Ar); 7.50-7.2 (m, 7H, Ar-H); 5.75 (d, J=7.41Hz, 1H, H<sub>1'</sub>  $\beta$ ); 5.20 (dd, J=15.22 Hz, CH<sub>2</sub> Bn); 5.15 (dd, 1H, H<sub>2'</sub>); 4.85 (dt, J=2.80 and 5.53Hz, 1H, H<sub>4'</sub>); 4.00 (dd, J<sub>3'-2'</sub>-J<sub>3'-4'</sub> 2.8 and 7.00 Hz, 1H, H<sub>3'</sub>); 3.70 (d, 2H, H<sub>5'</sub> H<sub>5''</sub>); 2-2.05 (2s, 6H, 2 CH<sub>3</sub> OAc); 1.85 (s, 3H, CH<sub>3</sub> OAc 5').

**N<sup>2</sup>-benzyl-N<sup>5</sup>-[2,3,5-tri-O-benzoyl-( $\beta$ -D)-ribofuranos-1-yl]-1,2,5-thiadiazolidin-3-one 1,1-dioxide 17a**

(way a) **Yield= 31%; Rf= 0.80** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95-5). [ $\alpha$ ]<sub>D</sub> = -17 (c=1, CHCl<sub>3</sub>); **1H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm): 7.35 (m, 20H, 4 Ar-H); 6.45 (d, J=7.3 Hz, 1H, H<sub>1'</sub>), 5.95 (dd, 1H, H<sub>3'</sub>); 5.80 (dd, 1H, H<sub>2'</sub>); 4.85 (m, 2H, H<sub>5'</sub> H<sub>5''</sub>); 4.5 (m, 1H, H<sub>4'</sub>); 4.65 (dd, J=15.20 Hz, 2H, CH<sub>2</sub> Bn); 4.00 (s, 2H, CH<sub>2</sub> Gly). **MS** (FAB>0, matrix NOBA) 671 (M+H)<sup>+</sup>, 445 (Osid.Cleav). **Anal.** (C<sub>35</sub>H<sub>30</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 62.68; H 4.47; N 4.17; S 4.77 found % C 62.55; H 4.39; N 4.21; S 4.88.

**N<sup>2</sup>-benzyl-N<sup>5</sup>-[2,3,5-tri-O-benzoyl-( $\beta$ -D)-ribofuranos-1-yl]-4-methyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 17b**

(way c) **Yield= 49%; Rf= 0.85** (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 97:3); [ $\alpha$ ]<sub>D</sub> = -32 (c=1, CHCl<sub>3</sub>). **1H NMR** (CDCl<sub>3</sub>,  $\delta$  ppm): 7.30-8.20 (m, 20H, Ar); 5.95 (d, J=7.40Hz, 1H, H<sub>1'</sub>  $\beta$ ); 5.75 (d, 1H, H<sub>3'</sub>); 5.70 (d, 1H, H<sub>2'</sub>); 4.70 (m, 2H, H<sub>5'</sub> H<sub>5''</sub>); 4.65 (dd, J= 15.20 Hz, 2H, CH<sub>2</sub> Bn ); 4.50 (q, J=7.30 Hz, 1H, C\*H); 4.10 (dd, 1H, H<sub>4'</sub>); 1.35 (d, 3H, CH<sub>3</sub> Ala). **MS** (FAB>0, matrix NOBA) 685 (M+H)<sup>+</sup>, 445 (Osid.Cleav ). **Anal.** (C<sub>36</sub>H<sub>32</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 63.15; H 4.67; N 4.09; S 4.67 found % C 63.41; H 4.74; N 4.13; S 4.68.

***N*-2-benzyl-*N*-5-[2,3,5-tri-*O*-benzoyl-(β-*D*)-ribofuranos-1-yl]-4-isopropyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 17c**

(way c) Yield= 52%; Rf= 0.63 (MeOH-CH<sub>2</sub>Cl<sub>2</sub> 95-5); [α]<sub>D</sub> = -10 (c=1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm): 5.75 (d, J=6.18 Hz, 1H, H<sub>1'</sub>); 5.6 (dd, 1H, H<sub>2'</sub>); 5.2 (dd, J<sub>3'-2'</sub> = 5.89 et 8.32 Hz, 1H, H<sub>3'</sub>); 4.65 (2d, J=15.32Hz, 2H, CH<sub>2</sub> Bn); 4.45 (dd, 1H, H<sub>4'</sub>); 4.20-4.30 (2dd, J<sub>gem</sub>=13 et J<sub>vic</sub>=7.12 Hz, 2H, H<sub>5'</sub>, H<sub>5''</sub>); 4.10 (2d, J=3.90 Hz, 1H, CH\*); 2.00 (2s, 9H, 3CH<sub>3</sub> OAc); 1.10 (m, 1H, iPr); 0.95-1.10 (2d, J=6.80 Hz, 6H, 2CH<sub>3</sub>). MS (FAB>0, matrix NOBA) 527 (M+H)<sup>+</sup>, 253 (Osid.Cleav). Anal. (C<sub>23</sub>H<sub>30</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 52.47; H 5.70; N 5.32; S 6.08 found % C 52.65; H 5.76; N 5.18; S 6.00.

***N*-2-benzyl-*N*-5-[2,3,5-tri-*O*-acetyl-(β-*D*)-ribofuranos-1-yl]-4-isobutyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 17d.**

(way c) Yield= 67%; Rf= 0.56 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95-5); [α]<sub>D</sub> = -72 (c=1, CHCl<sub>3</sub>). NMR (CDCl<sub>3</sub>, δ ppm) <sup>1</sup>H: 7.45-7.28 (m, 5H, Ar-H); 5.60 (d, J=7.82 Hz, 1H, H<sub>1'</sub>); 5.20 (dd, J=6.18 Hz, 1H, H<sub>2'</sub>); 5.08 (dd, 1H, H<sub>3'</sub>); 4.65 (2d, 15.21Hz, 2H, CH<sub>2</sub> Bn); 4.35 (dd, 1H, H<sub>5'</sub>); 4.30 (m, 3H, H<sub>4'</sub>); 4.25 (m, 1H, CH\*); 4.10 (2d, 1H, H<sub>5''</sub>); 2.15-1.90 (3s, 9H, 3 OAc); 1.75 (m, 2H, CH<sub>2</sub> β); 1.60 (m, 1H, CH); 0.70-0.80 (2d, J=6.50 Hz, 6H, 2CH<sub>3</sub>). <sup>13</sup>C: 19.2, 20.4, 21.6, 22.7, 23.6 (CH[CH<sub>3</sub>]<sub>2</sub> and 3xCH<sub>3</sub> OAc); 40.4 (Cβ); 45.9 (CH<sub>2</sub> Bn); 58.9 (C\*); 70.3 (C<sub>5</sub>); 77.3, 80.2, 82.0 (sug. C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>); 88.2 (sug. C<sub>1</sub>); 126.8, 128.1, 128.3 (C *o,m,p* Ar); 137.2 (C ipso); 170.8, 174.5 (CO Ac and CO heterocycl). MS (FAB>0, matrix NOBA) 541 (M+H)<sup>+</sup>, 259 (Osid.Cleav). Anal. (C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 53.33; H 5.92; N 5.18; S 5.92 found % C 53.56; H 5.98; N 5.12; S 5.88.

***N*-2,4-dibenzyl-*N*-5-[2,3,5-tri-*O*-acetyl-(β-*D*)-ribofuranos-1-yl]-1,2,5-thiadiazolidin-3-one dioxide 17e.**

(way c) Yield= 70%; Rf= 0.67 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); α<sub>D</sub> = -32 (c=1, CHCl<sub>3</sub>). NMR (CDCl<sub>3</sub>, δ ppm) <sup>1</sup>H: 7.25-7.35 (m, 10H, 2 Ar-H); 5.50 (d, J=7.82 Hz, 1H, H<sub>1'</sub>); 5.45 (dd, J=6.18 Hz, 1H, H<sub>2'</sub>); 5.15 (dd, 1H, H<sub>3'</sub>); 4.65 (dd, 15.21Hz, 2H, CH<sub>2</sub> Bn); 4.50 (m, 1H, C\*H); 3.90-4.10 (m, 3H, H<sub>5'</sub>, H<sub>5''</sub>, H<sub>4'</sub>); 3.10-3.30 (2dd, 2H, CH<sub>2</sub> Phe); 2.10-1.95 (2s, 9H, 3 OAc). <sup>13</sup>C: 21.5, 21.8 (3CH<sub>3</sub>; OAc); 35.5 (Cβ); 54.8 (CH<sub>2</sub> Bn); 59.8 (Cα); 64.2 (sug. C<sub>5</sub>); 69.7, 71.3, 72.4 (sug. C<sub>4</sub> C<sub>3</sub> and C<sub>2</sub>); 80.7 (C<sub>1</sub>); 128-130 (C Ar *o,m,p*); 135-137 (2 C ipso); 171.0-172.0, 174.5 (CO aglyc. and 3 CO Ac). MS (FAB>0, matrix NOBA) 575 (M+H)<sup>+</sup>, 259 (Osid.Cleav). Anal. (C<sub>27</sub>H<sub>30</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 56.44; H 5.22; N 4.87; S 5.57 found % C 56.65; H 5.17; N 4.78; S 5.48.

***N*-2-benzyl-*N*-5-[2,3,5-tri-*O*-benzoyl-(β-*D*)-ribofuranos-1-yl]-4-benzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 18**

(way a) Yield= 35%; Rf= 0.62 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 9-1); α<sub>D</sub> = -111 (c=1, MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm): 7.20-8.20 (m, 20H, 4 Ar-H); 6.25 (t, 1H, J= 5.24Hz, H<sub>1'</sub>); 6.00 (dd, J= 5.29 Hz, 1H, H<sub>2'</sub>); 5.95 (dd, 1H, H<sub>3'</sub>); 5.15 (d broad, 1H, NH, exch); 4.50-4.70 (m, 3H, H<sub>5'</sub>, H<sub>5''</sub> et H<sub>4'</sub>); 4.40 (m, 1H, CH\*); 3.20 (2d, 2H, CH<sub>2</sub> Bn). MS (FAB>0, matrix NOBA): 671 ([M+H]<sup>+</sup>); 445 (osidic cleavage). Anal. (C<sub>35</sub>H<sub>30</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 62.68; H 4.47; N 4.17; S 4.77 found % C 62.55; H 4.40; N 4.21; S 4.88.

**Hydrogenolysis.**

To an ethanolic solution of nucleoside (0.1 mM in 3 mL) were added 15 mg Palladium on charcoal (5 %) and ammonium formate (3Eq). The reaction was heating 30-45 mn to 60°C in a ballon equipped with a condenser. Alternatively the same quantity of *N*-benzyl nucleoside can be hydrogenolyzed under ultrasonic irradiation by cyclohexadiene (5 Eq) and Pd-C in a pear-shaped ballon cooled in a water bath. Vibracell 600W transmitter fitted with a microhorn was required; in that case the reaction time was 10 min. The reaction medium was filtered through celite and evaporated under reduced pressure; then the crude debenzylated compound was purified by column chromatography with dichloromethane as eluent.

***N*-5-[2,3,5-tri-*O*-acetyl-(β-*D*)-ribofuranos-1-yl]-4-isobutyl-1,2,5-thiadiazolidin-3-one 19d**

Yield= 75%; Rf= 0.55 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95-5). <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm): 5.55 (d, J<sub>1'-2'</sub> = 7.80 Hz, 1H, H<sub>1'β</sub>); 5.35 (dd, J<sub>3'-2'</sub> = 5.8Hz, J<sub>3'-4'</sub> = 2.5Hz, 1H, H<sub>3'</sub>); 5.10 (dd, J=7.75 and 5.80Hz, 1H, H<sub>2'</sub>); 4.35 (dd, J=3.00 et 12.34 Hz, 2H, H<sub>5'</sub> et H<sub>5''</sub>); 4.15 (t d, J=2.70 et 12.20 Hz, H<sub>4'</sub>); 4.05 (dd, J=12.66 et 2.70 Hz, 1H, CH\*); ; 2.05-2.10 (2s, 9H, 3 CH<sub>3</sub> Ac); 2.08 (m, 2H, CH<sub>2</sub> Leu); 1.68 (m, 1H, iPr); 1.10- 0.95 (2d, J=6.00 Hz, 6H, 2CH<sub>3</sub>Leu). MS (FAB>0, matrix NOBA) 451 (M+H)<sup>+</sup>, 259 (Osid.Cleav). Anal. (C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 45.33; H 5.77; N 6.22; S 7.11 found % C 45.12; H 5.64; N 6.25; S 7.02.

***N*-5-[2,3,5-tri-*O*-benzoyl-(β-*D*)-ribofuranos-1-yl]-4-benzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide 19e**

Yield= 68%; Rf= 0.58 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95-5) <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm): 7.25-7.35 (m, 5H, Ar-H); 5.35 (d, J<sub>1'-2'</sub> = 7.54Hz, 1H, H<sub>1'</sub>); 5.45 (dd, J=5.28 Hz, 1H, H<sub>2'</sub>); 5.12 (dd, J=5.30Hz, 1H, H<sub>3'</sub>); 4.50 (dd, 1H, C\*H); 3.90-4.10 (m, 3H, H<sub>5'</sub>, H<sub>5''</sub>, H<sub>4'</sub>); 3.10-3.30 (2dd, J<sub>gem</sub>=7.95 and J<sub>vic</sub>=16 Hz, 2H, CH<sub>2</sub> Phe); 2.08 (2s, 9H, 3OAc). MS (FAB>0, matrix NOBA) 485 (M+H)<sup>+</sup>, 259 (Osid.Cleav). Anal. (C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>10</sub>S) calc % C 49.58; H 4.95; N 5.78; S 6.61 found % C 49.67; H 5.02; N 5.85; S 6.54.

**Ammonolysis**

The tri-O-acyl nucleosides **18-19** were added at 0°C to a saturated solution of methanolic ammonia. The reaction was stirred overnight and the solvent was removed under vacuum. The residue was purified by column chromatography (eluent dichloromethane with methanol gradient 0-15%).

***N*<sup>5</sup>-[(β-D)-ribofuranos-1-yl]-4-isobutyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide **20d****

Yield= 85%; Rf= 0.48 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 85-15); [α]<sub>D</sub>=-44 (c=1 MeOH). **1H NMR** (DMSO d<sub>6</sub>, δ ppm): 6.35 (s, 1H, N-H exch); 5.25 (d, J= 7.60 Hz, 1H, H<sub>1'</sub>, β); 5.05 (mb, 3H, OH osid, exch); 4.30 (dd, J= 5.8Hz and =2.50 Hz, 1H, H<sub>3'</sub>); 4.25 (dd, 1H, H<sub>2'</sub>); 4.25 (m, 2H, H<sub>5'</sub> et H<sub>5''</sub>); 3.85 (m, H<sub>4'</sub>); 4.00 (dd, 1H, CH\*); 2.08 (m, 2H, CH<sub>2</sub> Leu); 1.65 (m, 1H, iPr); 0.95- 0.90 (2d, 6H, 2 CH<sub>3</sub> Leu). **MS** (FAB>0, matrix NOBA) 325 (M+H)<sup>+</sup>, 133 (Osid. Cleav). **Anal.** (C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>7</sub>S) calc % C 40.74; H6.17; N 8.64; S 9.88 found % C 40.45; H 6.13; N 8.65; S 9.74.

***N*<sup>5</sup>-[(β-D)-ribofuranos-1-yl]-4-benzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide **20e****

Yield= 88%; Rf= 0.52 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 85-15) [α]<sub>D</sub>=-47 (c=1 MeOH) **1H NMR** (DMSO d<sub>6</sub>, δ ppm): 7.25-7.35 (m, 6H, Ar-H and NH); 5.72 (t, 1H, 5'-OH, exch); 5.08 (d, J<sub>1'-2'</sub>=7.02 Hz, 1H, H<sub>1'</sub>); 4.35 (dd, J= 5.00 Hz, 1H, H<sub>3'</sub>); 5.12-5.06 (2 d, broad, 2H, 2'OH, 3'OH, exch), 4.17 (dd, J=5.30 Hz, 1H, H<sub>2'</sub>); 4.50 (dd, 1H, C\*H); 3.50-3.90 (m, 3H, H<sub>5'</sub>, H<sub>5''</sub>, H<sub>4'</sub>); 3.10-3.30 (2dd, J<sub>1</sub>=8.45 and J<sub>2</sub>=4.68 Hz, 2H, CH<sub>2</sub> Phe). **MS** (FAB>0, matrix NOBA) 359 (M+H)<sup>+</sup>, 133 (Osid. Cleav). **Anal.** (C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>7</sub>S) calc % C 46.92; H5.02; N 7.82; S 8.93 found % C 48.67; H 4.89; N 7.91; S 8.84.

***N*<sup>2</sup>-[(β-D)-ribofuranos-1-yl]-4-benzyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide **21****

Yield= 84%; Rf= 0.54 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 85-15); [α]<sub>D</sub>=-17 (c=1, MeOH). **1H NMR** (DMSO d<sub>6</sub>, δ ppm): 7.25-7.35 (m, 5H, Ar-H); 6.02 (t, 1H, J<sub>1'-2'</sub>= 7Hz, H<sub>1'</sub>); 5.25-5.00 (m broad, 4H, OH, NH, exch); 4.80 (dd, J= 5.29 Hz, 1H, H<sub>2'</sub>); 4.60 (dd, J=5.34 Hz, 1H, H<sub>3'</sub>); 3.55-3.90 (m, 3H, H<sub>5'</sub>, H<sub>5''</sub> et H<sub>4'</sub>); 4.35 (q, 1H, CH\*); 3.15 (2dd, Jgem=8.32 and Jvic=4.70 Hz, 2H, CH<sub>2</sub> Bn). **MS** (FAB>0, matrix NOBA) 359 (M+H)<sup>+</sup>, 133 (Osid. Cleav). **Anal.** (C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>7</sub>S) calc % C 46.92; H5.02; N 7.82; S 8.93 found % C 47.10; H 5.13; N 7.65; S 8.74.

**references**

1. a. Harmon E.H, Robins R.K, Townsend L.B. *Chemistry and Biology of nucleosides and nucleotides* Academic Press N.Y. **1978**. b. Périgaud C.; Gosselin G.; Imbach J-L. *Nucleosides Nucleotides*; **1992**, *11*, 903.
2. Nishimura H.; Mayama M.; Komatsu Y.; Shimaoka N.; Tanaka Y. *J. Antibiot* **1964**, *17*, 148.
3. El Barbary A.; Khodair A.I.; Pedersen E.B. *J. Org. Chem* **1993**, *58*, 5994-5999. El Barbary A.; Khodair A.I.; Pedersen E.B. *Arch. Pharm.* **1994**, *327*, 653. for a review concerning the hydantoinis see Lopez C.A.; Trigo G.C. *Adv. Heterocycl. Chem.* **1985**, *38*, 177. Concerning the chemistry of the sulfamides see: Benson G.A.; Spillane W.J. *Chem. Rev.* **1980**, *80*, 151.
4. a. Aouf N.; Dewynter G.; Montero J-L. *Tetrahedron Lett.* **1991**, *32*, 6545. b. Coker J.N.; Kohlhase W.L.; Martens T.F.; Rogers A.; Allan G.G. *J. Org. Chem* **1962**, *27*, 3201. c. Maki Y.; Masugi T.; Ozeki K. *Chem. Pharm. Bull. Jap* **1973**, *21*, 2466. d. Dewynter G.; Aouf N.; Ciron M.; Montero J-L. *Tetrahedron* **1993**, *49*, 65.
5. Dewynter G.; Montero, J-L. *C.R. Acad. Sci. Paris ; série II*, **1992**, *315*, 1675-1692
6. Mitsunobu O. *Synthesis* **1981**, 1.
7. a. Niedballa U.; Vorbrüggen H. *Angew. Chem. Int. Ed.* **1970**, *9*, 461. b. Niedballa U.; Vorbrüggen H. *J. Org. Chem.* **1974**, *39*, 3654; 3660; 3668; 3672. c. Vorbrüggen H.; Bennua B. *Chem. Ber.* **1981**, *114*, 1279. d. Vorbrüggen H.; Krolkiewicz K.; Bennua B. *Chem. Ber.* **1981**, *114*, 1234
8. a. Hilbert G.E.; Johnson, T.B. *J. Amer. Chem. Soc.* **1930**, *52*, 2001 and 4489. b. Pliml J.; Prystas M. *Adv. Heterocyclic Chem.* **1967**, *8*, 115.
9. a. Sato T.; Shimadate T.; Ishido Y. *Nippon Kagaku Zasshi* **1960**, *81*, 1440. b. Imai K.; Nohara H.; Honjo M. *Chem. Pharm. Bull.* **1966**, *14*, 1377.
10. a. Gosselin G.; Barrascut J-L; Imbach J-L. *L'actualité Chimique* **1979**, *3*, 7 and 4, 13 . b. Ueda T. *Chemistry of Nucleosides and Nucleotides*; Townsend L.B. Ed; Plenum Press, New York, **1988**.
11. The modeling calculations were made with the *GenMol* Program: Pèpe G.; Siri D. *Stud. Phys. Theor. Chem.* **1990**, *71*, 93.